Business
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024
About this update from Indaptus Therapeutics, Inc.
[{"type":"text","content":"Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, “We are thrilled with the progress we made in 2023, which was capped off in November when we announced that our lead candidate, Decoy20, demonstrated a broad immune response in patients following a single dose in the first cohort of our ongoing phase 1 study. More recently, in March 2024, we announced positive results from our second cohort. In close consultation with an independent Safety Review Committee, we are now initiating a multi-dose cohort. Our objective in this next part of the Phase 1 trial is to determine the safety of Decoy20, with multiple doses administered to the same patient, which we believe could also potentially enhance anti-tumor activity across various tumor types. As we are encouraged by these initial findings and by the anti-cancer activity we observed from multi-dosing in our pre-clinical models, we look forward to continuing our efforts to demonstrate safety and efficacy. We remain prudent in managing our cash position and furthering our research in a cost effective and efficient manner.” Key recent highlights: In March 2024, the Company announced positive results from its second cohort of its Phase 1 trial of Decoy20, where patients continued to exhibit a broad immune response. The results were reviewed by the Company and an independent Safety Review Committee and based on this review, it was recommended to proceed to the next part of the trial and enroll patients who will receive multiple doses of Decoy20. In January 2024, a key patent for the Company was approved by the European Patent Office which relates to the Company’s platform technology, covering a composition that can be used in the prevention or treatment of viral infections. In November 2023, the Company announced that Decoy20 demonstrated a broad immune response of more than fifty cytokines and chemokines in patients following a single dose in the first cohort of ongoing Phase 1 study. These data, as well a...